Session III:
September 17, 2025
1:00 – 3:30 PM ET
Rebroadcast: 6:30 – 9:00 PM ET
Reducing the Disparity with New Prostate Cancer Treatments and Clinical Trials
This session will review the latest developments in prostate cancer treatments and trends in clinical trials, assessing how these developments may potentially impact the racial disparity in prostate cancer. It will also examine active prostate cancer clinical trials to understand future treatment trends and outline existing opportunities for patients to participate in these trials.
Agenda:
Welcome: Artie Shelton, MD, COL (ret) U.S. Army, PHEN Ambassador
Opening Remarks and Moderator: Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN
Review of New Treatments and Trends: Richard Lee, MD, PhD, Clinical Co-Director: Claire and John Bertucci Center for Genitourinary Cancers at Mass General Cancer Center, Assistant Professor, Harvard Medical School
Where Are Clinical Trials Leading Us? Alicia K. Morgans, MD, Director of Adult Survivorship, Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School
Reviewing Emerging Clinical Trials: Keith Crawford, MD, PhD, and David Vasir, PhD, Senior Research Analyst, PHEN
Patient Clinical Trial Stories:
- Mr. Sherman Womack, Prostate Cancer Survivor
- Mr. Charles “Chuck” Christian, Prostate Cancer Survivor
- Mr. Art Cain, Prostate Cancer Survivor
Closing Remarks and Survey: Mr. Thomas A. Farrington
SPONSORS
PHEN thanks its sponsors for their support of the 2025 Summit.
